Given its central roles in cellular metabolic and growth signaling pathways, AMPK remains an appealing target for treating a range of pathologies associated with obesity and aging, including metabolic diseases such as obesity and type 2 diabetes (T2D). Here, PRKAB1 is linked to obesity due to melanocortin 4 receptor deficiency.